Should Patients Taking Sodium-Glucose Co-Transporter 2 Inhibitors Be Dropped From the Elective Surgical Program?

SODIUM-GLUCOSE cotransporter 2 inhibitors (SGLT2i) have proven to play a key role as pleiotropic drugs beyond the treatment of type 2 diabetes mellitus, promoting cardiovascular and renal-protective benefits even in nondiabetic patients. Moreover, SGLT2i have stepped into the spotlight in the management of patients with heart failure with a preserved ejection fraction and chronic kidney diseases. Empagliflozin reduced event rates of myocardial infarction, cardiovascular death, and strokes in type 2 diabetes mellitus patients compared with placebo, also decreasing hospitalization for cardiac failure.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Pro and Con Source Type: research